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Abstract: Effects of fructose 1,6-bisphosphate (F-1,6-P2) towards N-methyl-d-aspartate NMDA
excitotoxicity were evaluated in rat organotypic hippocampal brain slice cultures (OHSC) challenged
for 3 h with 30 µM NMDA, followed by incubations (24, 48, and 72 h) without (controls) and
with F-1,6-P2 (0.5, 1 or 1.5 mM). At each time, cell necrosis was determined by measuring LDH
in the medium. Energy metabolism was evaluated by measuring ATP, GTP, ADP, AMP, and ATP
catabolites (nucleosides and oxypurines) in deproteinized OHSC extracts. Gene expressions of
phosphofructokinase, aldolase, and glyceraldehyde-3-phosphate dehydrogenase were also measured.
F-1,6-P2 dose-dependently decreased NMDA excitotoxicity, abolishing cell necrosis at the highest
concentration tested (1.5 mM). Additionally, F-1,6-P2 attenuated cell energy imbalance caused by
NMDA, ameliorating the mitochondrial phosphorylating capacity (increase in ATP/ADP ratio)
Metabolism normalization occurred when using 1.5 mM F-1,6-P2. Remarkable increase in expressions
of phosphofructokinase, aldolase and glyceraldehyde-3-phosphate dehydrogenase (up to 25 times
over the values of controls) was also observed. Since this phenomenon was recorded even in OHSC
treated with F-1,6-P2 with no prior challenge with NMDA, it is highly conceivable that F-1,6-P2 can
enter into intact cerebral cells producing significant benefits on energy metabolism. These effects
are possibly mediated by changes occurring at the gene level, thus opening new perspectives for
F-1,6-P2 application as a useful adjuvant to rescue mitochondrial metabolism of cerebral cells under
stressing conditions.
Keywords: fructose-1,6-bisphosphate; N-methyl-d-aspartate; excitotoxicity; energy metabolism;
mitochondrial dysfunction; organotypic hippocampal brain slice cultures
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1. Introduction
Brain damage caused by acute (ischemia, stroke, hypoxia, traumatic brain injury) and chronic
neurological disorders (Alzheimer’s disease, Parkinson’s disease, multiple sclerosis) has some
common biochemical features including ionic imbalance [1], cell energy failure [2] and increase
in the release of neurotransmitters with inhibition of their reuptake [3]. This last phenomenon mainly
involves glutamate, the most important excitotoxic neurotransmitter. Glutamate binds to ionotropic
N-methyl-d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA),
kainic acid rceptors, as well as to metabotropic receptors, promoting a major influx of calcium into
neurons and astrocytes. Re-uptake by astrocytes is crucial to terminate glutamate signaling and to
prevent the insurgence of the dangerous phenomenon known as glutamate excitotoxicity [4]. Using
NMDA, which acts as an agonist for NMDA receptor, it is possible to mimic glutamate excitotoxicity
in various experimental conditions [5,6].
Under pathological conditions, the glutamate-glutamine cycle involving neurons and astrocytes
is impaired leading to glutamate excitotoxicity with massive calcium influx within mitochondria.
Calcium overload initiates excitatory events involving free radical generation, triggering of apoptosis
through processing caspase cleavage, opening of the mitochondrial permeability transition pore.
This last event causes the depolarization of the mitochondrial inner membrane damaging the major role
of mitochondria, i.e., the correct functioning of the electron transfer chain (ETC) coupled to oxidative
phosphorylation (OXPHOS), and causing transient or permanent mitochondrial malfunction [2,5].
The consequences are a decreased efficiency in adenosine triphosphate (ATP) synthesis, with imbalance
in ATP production and consumption and cell energy deficit. Therefore, decrease in the neuronal
ATP levels contributes to exacerbate the imbalance in ionic homeostasis in brain cells and creates a
vicious circle linking glutamate excitotoxicity, mitochondrial activity and cell energy metabolism [7,8].
Additionally, malfunctioning mitochondria cause increased production of reactive oxygen and nitrogen
species (ROS and RNS), leading to the insurgence of oxidative/nitrosative stress [9], and release of
proapoptotic factors, with consequent activation of caspases and the intrinsic apoptotic pathway [10].
Therefore, glutamate excitotoxicity has been considered since long time a strategic target for
therapeutic interventions in brain insults of different etiology [11]. Despite positive results obtained
in cellular and animal models targeting NMDA and AMPA receptors with different promising
drugs [12,13], the subsequent clinical trials failed to improve outcome of the patients [14,15] so that
effective pharmacologic treatments to decrease glutamate excitotoxicity in humans are still lacking.
Fructose-1,6-bisphosphate (F-1,6-P2) is a six carbon monosaccharide, found in both prokaryotes and
eukaryotes, and produced in the third reaction of glycolysis through the activity of phosphofructokinase
I. In the last decades, exogenous administration of F-1,6-P2, in concentrations (1.5–10 mM) largely
exceeding its intracellular concentration (1–5 µM) [16,17], has been used in a variety of pathological
conditions in both preclinical and clinical studies [18]. Particularly, F-1,6-P2 improved myocardial
energy metabolism [19] and decreased oxidative stress in experimental models of anoxia and
re-oxygenation [20], reduced post-ischemic ventricular dysfunctions [21], improved outcome after
circulatory arrest in pigs [22].
Clinically, F-1,6-P2 improved hemodynamic in patients with altered ventricular functions [23]
and protected myocardium during coronary bypass surgery [24]. In models of brain injury, F-1,6-P2
protected neuronal integrity after circulatory arrest in pigs [25], preserved cerebral energy metabolism
after brain ischemia [26], protected hippocampal neurons by repeated febrile convulsions [27], preserved
glucose metabolism and decreased oxidative stress caused by experimental sepsis [28]. It is worth
recalling that in different experimental conditions of hypoxia/ischemia F-1,6-P2 administration did not
show significant beneficial effects on high energy phosphate metabolism [29,30].
Organotypic slice cultures represent a valid experimental model, maintaining neuronal maturation
and plasticity, useful to evaluate experimental insults and drug treatments that can be followed
for various days in vitro [31]. Using this model, toxicity of the Aβ oligomer 1–40, characteristic
of the Alzheimer’s disease, has been evaluated in mixed neuronal-glial cerebellar cultures and
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organotypic cerebellar cultures [32]. Organotypic hippocampal slice cultures (OHSC) specifically uses
hippocampal slices, mainly obtained from neonatal rats, to study the biochemical, morphological and
functional characteristics of both neurons and glial cells. This model is suitable to study neurotoxicity,
neuroprotection, neuronal networks or tumor invasion [33], and even to effectively mimic cellular
damages induced by traumatic brain injury [34].
With the aim to clarify the effects of exogenous F-1,6-P2, in this study we tested the benefits of
increasing concentrations of F-1,6-P2 on NMDA excitotoxicity induced in rat OHSC by measuring release
of lactate dehydrogenase (LDH) in the medium and concentrations of various metabolites related to
energy metabolism (ATP, GTP, ADP, AMP, oxypurines, nucleosides, lactate). The expression of the genes
encoding for 6-phosphofructo-1-kinase (PFKL), aldolase (ALDOC) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), were also considered.
2. Results
2.1. NMDA Cytotoxicity and Protection by F-1,6-P2
The cytotoxic effects of NMDA on OHSC were clearly evidenced by the time-dependent increase
of LDH in the medium (Figure 1). At 24, 48 and 72 h after the 3 h challenge with 30 µM NMDA,
OHSC had LDH values were 4.7, 5.1 and 6.2 times higher than the values determined in the medium
of control OHSC at the same time points (p < 0.001). The supplementation to the culture medium of
NMDA-treated OHSC with 0.5, 1 or 1.5 mM F-1,6-P2 provoked a dose-dependent beneficial effect,
as indicated by the decreased release of LDH (Figure 1). All samples receiving F-1,6-P2 in the recovery
phase, for 24, 48 and 72 h post challenge with 30 µM NMDA, showed lower LDH values in the medium
at any time point, when compared to the corresponding times of OHSC with no supplementation
(p < 0.001). It is worth noting that 1.5 mM F-1,6-P2 completely abolished the cytotoxic effects of NMDA,
so that LDH values in the medium of these cultures were not significantly different from those found
in controls at the corresponding time points (Figure 1).
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Figure 1. Protective effects of F-1,6-P2 on cell necrosis in NMDA-treated OHSC. OHSC were 
challenged with 30 μM NMDA for 3 h and then incubated without and with increasing 
concentrations of F-1,6-P2 (0.5, 1 and 1.5 mM) for different times (24, 48 and 72 h). Control OHSC 
were incubated for the same time intervals, with no prior NMDA treatment or F-1,6-P2 addition. Cell 
necrosis was deducted by the amount of LDH released in the culture medium and expressed as mU 
of enzyme activity/L of medium (1 U = 1 μmol/min of substrate consumed). Histograms are the mean 
of 6 different OHSC preparations. Standard deviations are represented by vertical bars. * 
Significantly different from corresponding time of control OHSC, p < 0.001. ** Significantly different 
from corresponding time of NMDA-challenged OHSC with no F-1,6-P2 supplementation, p < 0.001. 
Figure 1. Protective effects of F-1,6-P2 on cell necrosis in NMDA-treated OHSC. OHSC were challenged
with 30 µM NMDA for 3 h and then incubated without and with increasing concentrations of F-1,6-P2
(0.5, 1 and 1.5 mM) for different times (24, 48 and 72 h). Control OHSC were incubated for the same
time intervals, with no prior NMDA treatment or F-1,6-P2 addition. Cell necrosis was deducted by the
amount of LDH released in the culture medium and expressed as mU of enzyme activity/L of medium
(1 U = 1 µmol/min of substrate consumed). Histograms are the mean of 6 different OHSC preparations.
Standard deviations are represented by vertical bars. * Significantly different from corresponding time
of control OHSC, p < 0.001. ** Significantly different from corresponding time of NMDA-challenged
OHSC with no F-1,6-P2 supplementation, p < 0.001.
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2.2. NMDA-Induced Imbalance of OHSC Energy Metabolism and Protection by F-1,6-P2
Prolonged recovery following incubation of OHSC with 30 µM NMDA for 3 h caused a
time-dependent decline in the cell energy state. As shown in Figure 2, ATP (panel A) and GTP
(panel B) concentrations in NMDA-pretreated OHSC at 24, 48 and 72 h incubation were 15%, 31%
and 46%, and 37%, 32% and 39% lower, respectively, than corresponding values detected in controls
(p < 0.001). The addition during the recovery phase of increasing concentrations of F-1,6-P2 (0.5,
1 or 1.5 mM), to the medium of 30 µM NMDA-pretreated OHSC, significantly protected cell energy
metabolism. Levels of both high energy phosphates (ATP and GTP) in OHSC receiving F-1,6-P2 were
significantly higher than the values recorded in OHSC with no supplement during recovery. It is
particularly relevant that the beneficial effects produced by the presence of 1.5 mM F-1,6-P2, during
recovery of OHSC after challenging with 30 µM NMDA, were capable to allow measuring values of
ATP and GTP that were not different from those found in control OHSC.
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The consequence of OHSC energy metabolism imbalance, caused by 30 µM NMDA,
was particularly evident when considering variations of AMP during the recovery phase, rather
than when observing ADP changes (Figure 3). At 24, 48 and 72 h post NMDA challenge, ADP and AMP
were 1.2, 1.2 and 1.5, and 2.5, 3.5 and 3.8 times higher than the values determined at corresponding
times in control OHSC (p < 0.001). Addition of 1 and 1.5 mM F-1,6-P2 completely abolished the negative
effect on ADP concentrations caused by pre-treatment with 30 µM NMDA (p < 0.001 compared to
corresponding times of OHSC pretreated with NMDA; not significant compared to corresponding
ti es of control OHSC). F-1,6-P2 was less effective in normalizing AMP concentrations. Even at
the highest dose tested (1.5 mM), AMP in OHSC (pretreated with 30 µM NMDA) receiving F-1,6-P2
during recovery was significantly lower than values found at corresponding times in OHSC (pretreated
with 30 µM NMDA) with no addition during recovery (p < 0.001), but also significantly higher than
concentrations easured in control OHSC (p < 0.001).
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were challenged with 30 μM NMDA for 3 h and then incubated without and with increasing 
concentrations of F-1,6-P2 (0.5, 1 and 1.5 mM) for different times (24, 48 and 72 h). Control OHSC 
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are the mean of 6 different OHSC preparations. Standard deviations are represented by vertical bars. 
* Significantly different from corresponding time of control OHSC, p < 0.001. ** Significantly different 
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Data illustrated in Figure 4 indicate that using two indexes representing itochondrial
phosphorylating capacity (ATP/ADP ratio (Figure 4a) and cell energy wellness (ECP = energy charge
potential = (ATP + 1/2ADP)/(ATP + ADP + AMP) (Figure 4b), it was possible to evidence that 3 h
incubation with 30 µM NMDA caused long lasting negative effects on energy etabolism of OHSC
cultures, that progressed by prolonging the time of recovery (24, 48 and 72 h). Dose-dependent ability
to ameliorate both parameters was observed when supplementing 30 µM DA-pretreated O SC
ith F-1,6-P2 0.5, 1 and 1.5 . At the highest dose tested (1.5 ), O SC receiving F-1,6-P2 had
values of the ATP/ADP ratio and ECP not different fro those calculated in control OHSC.
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Figure 4. Effects of F-1,6-P2 on en rgy metabolism derangement in NMDA-treated OHSC. OHSC were
challenged with 30 µM NMDA for 3 h and then incubated without an ith incre sing conce t atio s
of F-1,6-P2 (0.5, 1 and 1.5 mM) for different times (24, 48 and 72 h). Control OHSC were incubated for
th same time intervals, with no prior NMDA treatment or F-1,6-P2 addition. ATP/ADP ratio (a) reflects
the phosphorylating capacity of mitoc ondria. ECP (b) indicates t e cell energy well ess, according
to the equation: ECP = ATP + 1/2ADP/(ATP + ADP + AMP). Histograms are the mean of 6 different
OHSC preparations. Standard deviations re represe ted by vertical bars. * Significantly different from
corresponding tim of control OHSC, p < 0.001. ** Significantly different from corresponding time of
NMDA-challenged OHSC with no F-1,6-P2 supplementation, p < 0.001.
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2.3. Effects of F-1,6-P2 on Adenine Nucleotide Catabolism and Lactate Production in OHSC Challenged with
NMDA
Quantification in the culture medium of products generating from ATP dephosphorylation
(adenosine, inosine, hypoxanthine, xanthine and uric acid), evidenced the activation of the degradation
pathway of adenine nucleotide catabolism in OHSC pretreated with 30 µM NMDA and then allowed
to recover for 24, 48 and 72 h (Figure 5). Both sum of nucleosides (Figure 5a) and sum of oxypurines
(Figure 5b) progressively increased during the time of recovery (p < 0.001 compared to corresponding
times of control OHSC), with sum of oxypurines showing the most dramatic increases in the medium
(5.8, 4.2 and 4.8 times at 24, 48 and 72 h, respectively; p < 0.001).
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The release of lactate in the medium of OHSC after challenge with 30 µM NMDA (Figure 6)
increased by 2.5, 3.9 and 3.8 times, respectively, at 24, 48 and 72 h, compared to values measured at
corresponding times in control OHSC (p < 0.001). Significantly lower values were found at any time
point when F-1,6-P2, at any dose tested, was added to the medium of OHSC during the recovery phase
(p < 0.001). However, at 48 and 72 h after NMDA challenge, cultures supplemented with F-1,6-P2 had
lactate release in the medium higher than that measured in control OHSC (p < 0.001).
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Figure 6. Effects of F-1,6-P2 on lactate production in NMDA-treated OHSC. OHSC were challenged
with 30 µM NMDA for 3 h and then incubated without and with increasing concentrations of F-1,6-P2
(0.5, 1 and 1.5 mM) for different times (24, 48 and 72 h). Control OHSC were incubated for the same time
intervals, with no prior NMDA treatment or F-1,6-P2 addition. Lactate was measured enzymatically
in deproteinized cell extracts. * Significantly different from corresponding time of control OHSC,
p < 0.001. ** Significantly different from corresponding time of NMDA-challenged OHSC with no
F-1,6-P2 supplementation, p < 0.001.
2.4. Expression of Genes Regulating the Synthesis of Glycolytic Enzymes Involved in F-1,6-P2 Metabolism
Under all experimental conditions, we determined the expression of genes controlling the
synthesis of the isoform L of 6-phospho-1-fructokinase (PFKL), aldolase (brain gene = ALDOC) and
glyceraldehyde-3-phospate dehydrogenase (GAPDH). These three enzymes are sequentially positioned
along the glycolytic pathway providing to the synthesis of F-1,6-P2 from fructose-6-phosphate and ATP
(PFKL), to its hydrolysis into glyceraldehyde-3-phospate and dihydroxyacetone-3-phosphate (aldolase)
and to the oxidation and phosphorylation of glyceraldehyde-3-phospate into glycerate-1,3-bisphosphate
(GAPDH).
Neither control OHSC nor OHSC pretreated with 30 µM NMDA and incubated for 24, 48 and
72 h of recovery showed any difference in the gene expression of PFKL, at any time point (Figure 7).
When 0.5 mM F-1,6-P2 was added to the medium after challenge with 30 µM NMDA, PFKL
expression at 24, 48 and 72 h increased by 6, 10 and 14 times, respectively, over the values of control
OHSC at corresponding time points (p < 0.001). Using 1 mM F-1,6-P2 this increase was 7, 14 and 19
times at 24, 48 and 72 h, respectively (p < 0.001 compared to control OHSC). At the highest dose of
F-1,6-P2 tested (1.5 mM), expression of PFKL at the same time points was 17, 20 and 27 times higher
than the values recorded in control OHSC (p < 0.001).
Differently, 0.5 and 1 mM F-1,6-P2 significantly affected ALDOC expression, after challenge with
NMDA (Figure 8a), only after 72 h. Using these two dosages, expression of ALDOC increased by 5 and
7 times over the value measured in control OHSC (p < 0.001). When 1.5 mM F-1,6-P2 was added to the
medium during the recovery phase, ALDOC increased 1.7 and 8 times at 48 and 72 h, respectively,
in comparison with values recorded at corresponding times in control OHSC (p < 0.001). Similarly,
0.5 and 1 mM F-1,6-P2 produced 13 and 16 times increase, respectively, in GAPDH expression only after
72 h of recovery post challenge with NMDA (p < 0.001 compared to the same time of control OHSC)
(Figure 8b). Again, the effect on this gene expression of NMDA pretreated OHSC supplemented with
1.5 mM F-1,6-P2 was significant either at 48 or at 72 h when 2 and 23 times higher values than those of
control OHSC were recorded (p < 0.001).
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In a different set of experiments, we evaluated the effects of the addition of increasing 
concentrations of F-1,6-P2 on the gene expressions of PFKL, ALDOC and GAPDH of OHSC with no 
previous challenge with NMDA. Data summarized in Table 1 showed that F-1,6-P2 caused the 
Figure 7. Effects of F-1,6-P2 on gene expression of 6-phospho-1-fructokinase (PFKL) in NMDA-treated
OHSC. OHSC were challenged with 30 µM NMDA for 3 h and then incubated without and with
increasing concentrations of F-1,6-P2 (0.5, 1 and 1.5 mM) for different times (24, 48 and 72 h). Control
OHSC were incubated for the same time intervals, with no prior NMDA treatment or F-1,6-P2 addition.
Semi-quantitative PFKL expression was determined in cell extracts, relatively to the housekeeping
gene β-2-microglobulin (B2M). Histograms are the mean of 6 different OHSC preparations. Standard
deviations are represented by vertical bars. * Significantly different from corresponding time of control
OHSC, p < 0.001. ** Significantly different from corresponding time of NMDA-challenged OHSC with
no F-1,6-P2 supplementation, p < 0.001.
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In a different set of experiments, we evaluated the effects of the addition of increasing concentrations
of F-1,6-P2 on the gene expressions of PFKL, ALDOC and GAPDH of OHSC with no previous challenge
with NMDA. Data summarized in Table 1 showed that F-1,6-P2 cau ed the increase f the three genes
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with levels of overexpression slightly lower than those found when OHSC were previously challenged
with 30 µM NMDA.
Table 1. Relative expression of genes encoding for the glycolytic enzymes 6-phosphofructo-1-kinase
(PFKL), aldolase (ALDOC) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in OHSC
incubated for different times in presence of increasing concentrations of F-1,6-P2.
Treatment Time(Hours)
PFKL/BD2M
(Fold Increase)
ALDOC/BD2M
(Fold Increase)
GAPDH/BD2M
(Fold Increase)
Control
24 1.10 ± 0.30 1.02 ± 0.18 1.15 ± 0.13
48 1.07 ± 0.26 1.15 ± 0.21 1.07 ± 0.20
72 0.98 ± 0.21 1.08 ± 0.23 0.99 ± 0.14
0.5 mM F-1,6-P2
24 4.64 ± 0.62 a,b 0.94 ± 0.11 1.14 ± 0.25
48 7.89 ± 0.88 a,b 1.09 ± 0.18 1.09 ± 0.18
72 11.26 ± 1.23 a,b 3.67 ± 0.43 a,b 8.38 ± 1.23 a,b
1 mM F-1,6-P2
24 5.16 ± 0.49 a,b 1.11 ± 0.17 1.06 ± 0.16
48 10.54 ± 1.18 a,b 0.97 ± 0.09 0.94 ± 0.10
72 15.92 ± 1.66 a,b 4.71 ± 0.75 a,b 11.55 ± 2.03 a,b
1.5 mM F-1,6-P2
24 9.75 ± 0.95 a,b 1.21 ± 0.26 1.19 ± 0.21
48 14.21 ± 1.58 a,b 1.34 ± 0.31 1.32 ± 0.18
72 21.09 ± 2.36 a,b 6.92 ± 0.95 a,b 17.46 ± 2.67 a,b
Values are the mean ± S.D. of 5 experiments from 5 different OHSC preparations and are expressed as fold increase
respect to values recorded in control OHSC at corresponding times (see Figure 7 for control values of PFKL and
Figure 8 for those of ALDOC and GAPDH). a Significantly different from controls, p < 0.001. b Significantly different
from values recorded in OHSC previously challenged with 30 µM NMDA and then supplemented with the same
F-1,6-P2 concentration, p < 0.01.
3. Discussion
The phenomenon of glutamate-mediated excitotoxicity plays a central role in acute and chronic
neurodegenerations and represents a target for new therapeutic approaches in numerous pathological
states, including cerebral ischemia, stroke, traumatic brain injury [35–37]. Organotypic hippocampal
slice cultures represent a useful in vitro model with which to study not only the effects of excitotoxicity
(triggered by the challenge with NMDA) on nervous cell metabolism and functions [38] but also to
evaluate efficacy of drug treatments [39].
In the present study, treatment of OHSC with 30 µM NMDA for 3 h at 37 ◦C induced long
lasting damages to nervous cells progressing during the whole observational time (72 h). Cell death
increased by increasing the time of incubation and was accompanied by decrease in ATP concentration.
Although part of this effect might be related to decrease in the number of living cells, it is worth
underlining that dramatic decrease in the ATP/ADP ratio, which is considered a good indicator of
the mitochondrial phosphorylating capacity [40], and remarkable reduction of the ECP, representing
a measure of the energy wellness of the cell [41], were recorded. In addition, the derangement of
energy metabolism in OHSC after treatment with NMDA was also evidenced by the almost three times
and six times increase in AMP and oxypurines, respectively, strongly demonstrating activation of the
adenine nucleotide degradation pathway depleting the cellular content of the high-energy phosphate
compounds. In this context of sustained dysmetabolism, cerebral cell response was to increase the rate
of glycolysis (increase in lactate efflux in the medium, Figure 6) without changing the expression either
of the gene encoding for the key regulatory enzyme of glycolysis (PFKL) or of the genes encoding
for the immediately following enzymes of the glycolytic pathway (ALDOC and GAPDH) (Figures 7
and 8). This phenomenon, termed as hyperglycolysis, has been shown to occur following TBI [42] and
has been associated to the sub-chronic phase following severe (but not mild) TBI [7].
The addition to the incubation medium of F-1,6-P2 following the induction of excitotoxicity
had dose-dependent beneficial effects on cerebral cell survival and metabolism. Our results seem to
inversely associate reduction of cell mortality with improvement in energy metabolism caused by
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F-1,6-P2. Particularly at the highest concentration tested, F-1,6-P2 restored ATP and GTP concentrations
to values detected in control OHSC. ATP rescue was accompanied by high value of the ATP/ADP ratio
and ECP, and decreased efflux of lactate in the medium (but still higher than control OHSC), thus
indicating no mitochondrial dysfunction and normal cell energy state.
Results of the gene expression analysis clearly showed, for the first time to the best of our knowledge,
that the gene encoding for 6-phosphofructo-1-kinase (PFKL) was time and dose-dependently increased
by any dose of F-1,6-P2 tested. Additionally, at the longest time of incubation post NMDA challenge,
a dose dependent increase in ADLOC and GAPDH was also observed.
These results strongly suggest that F-1,6-P2, notwithstanding is a highly negatively charged
molecule at physiological pH, can enter the cell in its intact form where it acts as a neuroprotector
against NMDA excitotoxicity. While at physiological concentration the biochemical role of F-1,6-P2
as a substrate of aldolase and a positive allosteric modulator of 6-phosphofructo-1-kinase is well
established [43], little is known either about the mechanisms involved in its cellular uptake or about
the biochemical processes involved in its beneficial effects under conditions of cell sufferance.
Using the isolated Langendorff-perfused rat heart, we have previously shown that exogenous
F-1,6-P2 is actively metabolized by intact cardiomyocytes [44] and taken up through the involvement
of the dicarboxylate transporter [45]. Since this transporter has been found in cerebral cells [46,47], it is
conceivable hypothesizing that, even under the experimental conditions used in the present study,
F-1,6-P2 might cross the nervous cell membranes involving the same transport mechanism.
Although it has not been demonstrated whether F-1,6-P2 is a privileged, advantageous substrate
for cell metabolism (its use in alternative to glucose would allow saving two ATP-dependent
phosphorylating reactions, leading to a net production of 4 ATP moles/mole of F-1,6-P2 consumed,
rather than 2 moles of ATP/mole of glucose consumed through glycolysis), several studies have
shown that exogenous F-1,6-P2 at various dosage improves energy metabolism under conditions of
cellular energetic crisis [19–25]. These effects, causing the increase in the concentrations of high-energy
phosphates and of the cell phosphorylation potential [19,20,48], have been connected, in part, to a
decrease in intracellular free calcium ions having positive influence on mitochondrial functions [49].
According to the results of the gene expressions of PFKL, ALDOC and GAPDH it is possible adding
to the list of changes of cell metabolism/functions, induced by exogenous F-1,6-P2, this previously
unknown and unexpected effect. If the increase in ALDOC and GAPDH can be interpreted as an
adaptive mechanism, occurring only after relatively long time of incubation with F-1,6-P2 and after
PFKL have remarkably increased, the augmentation of PFKL is certainly a direct consequence of the
presence of increasing concentrations of F-1,6-P2 in the OHSC culture medium during the recovery
phase, post NMDA challenge. Since these overexpressions were also measured in OHSC incubated
for the same times with the same dosages of F-1,6-P2, but without prior challenge with NMDA, it is
possible to exclude that uptake of F-1,6-P2 might take place only under conditions of altered cell
membrane permeability, as it occurs after NMDA treatment [50].
It can be hypothesized that the overexpressions of the aforementioned genes result in a robust
increase of the glycolytic flow. If occurring during mitochondrial dysfunction, higher glycolytic rates
may be deleterious for cerebral cells and provoke hyperglycolysis [7,50]. Differently, when taking
place with normal mitochondrial functions, higher glycolytic rates lead to improvement of cell energy
state [7,51]. Furthermore, various studies underlined the roles of ALDOC and GAPDH in the cross-talk
between neurons and astrocytes and in the physiopathological mechanisms regulating cerebral cell
energy metabolism [52–57].
Although further studies in laboratory animals are needed, these results corroborate previous
observations showing the beneficial effects of F-1,6-P2 on brain metabolism and functions under
various stressing conditions [19–26]. The previously unreported effects of this drug on the expressions
of genes encoding for key glycolytic enzymes represent a new evidence that exogenous F-1,6-P2 might
represent an additional valid substrate for cell energy metabolism, of particular efficacy during period
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of metabolic sufferance characterized by mitochondrial dysfunction. Studies to determine the transport
mechanisms involved in the cellular uptake of exogenous F-1,6-P2 are certainly needed.
4. Materials and Methods
4.1. Organotypic Hippocampal Slice Cultures
The organotypic hippocampal slice cultures (OHSC) were prepared using a method described in
detail elsewhere [34,58] and all procedures used were in accordance with UK regulations under the
Animals (Scientific Procedures) Act of 1986 and approved by the Ethical Committee of the Catholic
University of Rome (number 1F295.52, date 10-20-2017). Briefly, hippocampi from 8 to 10 days old
Wistar rats were isolated and sliced at a thickness of 400 µm, using a McIlwain tissue chopper (Harvard
Apparatus, Edenbridge, UK). The slices were then placed in plate inserts, 0.4 mm Millicel membrane
and 30 mm diameter, previously treated with a coating solution of 320 µg/mL of poly-d-lysine (Sigma,
St. Louis, MO, USA) and 80 µg/mL of laminin (Sigma) in sterile distilled water. The cultures were
fed initially in 1200 µL NeuroBasal-A medium (Invitrogen, Loughborough, UK), containing B27
supplement (Invitrogen) (1 mL/100 mL medium), 5 mg/mL glucose (Sigma), 1 mM glutamine (Sigma)
and incubated at 37 ◦C under humidified atmosphere of 95% O2 + 5% CO2. After two days in vitro,
the NeuroBasal-A medium was replaced with full serum-containing medium, consisting of 25%
heat-inactivated horse serum, 25% Hanks’-balanced salt solution, 50% minimum essential medium (all
Invitrogen), 1 mM glutamine (Sigma), and 5 mg/mL D-glucose (Sigma). After approximately 10 days,
when cultures adhered to the membrane and showed clear definition of the neuronal regions CA1,
CA3 and dentate gyrus, fresh medium was added to the healthy cultures and the wells were used to
perform the experiments.
4.2. NMDA and F-1,6-P2 Treatments
Excitotoxic effects of NMDA to OHSC were induced by adding 30 µM NMDA to culture medium
for 3 h [59]. This NMDA concentration and timing of NMDA exposure were the best conditions causing
significant (but not excessive) cell death and remarkable metabolic changes to OHSC, as evidenced by
previous studies [59] and by preliminary experiments in which lower NMDA doses and/or shortest
incubation times were tested (data not shown). At the end of this incubation time, the NMDA-containing
medium was removed and OHSC were allowed to recover in fresh full serum-containing medium
without or with the addition of F-1,6-P2 (0.5, 1 and 1.5 mM). The recovery time at 37 ◦C under
humidified atmosphere of 95% air and 5% CO2 was prolonged for 24, 48 or 72 h. At each time point,
the medium was collected and stored at −80 ◦C for LDH and lactate assays, the cultures were washed
3 times with 500 µL of ice-cold PBS and then processed to extract RNA for real-time quantitative
PCR analysis.
In a different set of experiments, using the same treatment protocol, cultures were washed 3 times
with 500 µL of ice cold PBS and then immediately deproteinized with 500 µL of an ice cold organic
solvent mixture (75% CH3CN + 25% 10 mM NaH2PO4, pH 7.4). This processing allowed obtaining
samples suitable for the subsequent HPLC analysis of low molecular weight metabolites [60].
In a specific set of experiments, dedicated to evaluating the effects on gene expression, OHSC
were incubated with F-1,6-P2 (1.5 mM) for 24, 48 and 72 h with no previous challenge with NMDA.
Results obtained under the different experimental conditions were compared to OHSC incubated for
the same times with neither previous NMDA challenge nor addition of F-1,6-P2.
4.3. LDH and Lactate Assays
One hundredµL of each sample of culture medium from the various OHSC were used to determine
LDH release as a measure of cell death. The enzyme activity was determined spectrophotometrically
(Agilent 89090A, Agilent Technologies, Santa Clara Ca, CA, USA) following the time-dependent
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disappearance of NADH at 340 nm in a mixture containing 2 mM pyruvate, 200 µM NADH and 20 mM
Tris-HCl buffer pH 7.6, according to standardized protocol [61].
The spectrophotometric determination of lactate was carried out following the method
described by Artiss et al. [62]. Briefly, the reaction mixture contained 100 mM Tris-HCl, 1.5 mM
N-ethyl-N-2-hydroxy-3-sulfopropyl-3-methylalanine, 1.7 mM 4-aminoantipirine, 5 IU horseradish
peroxidase. One hundred µL of each sample were added to the mixture, let to stand for 5 min and
read at 545 nm wavelength. The reaction was started with the addition of 5 IU of lactate oxidase to
the cuvette (finale volume = 1 mL) and it was considered ended when no change in absorbance was
recorded for at least 2 min. To calculate lactate, the difference in absorbance at 545 nm wavelength
(∆abs) of each sample was interpolated with a calibration curve obtained by plotting ∆abs measured
in standard solutions of lactate with increasing known concentrations.
4.4. HPLC Analysis of Metabolites
The simultaneous separation of high-energy phosphates (ATP, ADP, AMP, GTP), purine nucleosides
(inosine, adenosine, guanosine) and oxypurines (hypoxanthine, xanthine, uric acid) in the protein-free
cell extracts (200 µL) was carried out using previously established ion pairing HPLC methods which
utilize tetrabutylammonium hydroxide as the pairing reagent [63]. Separation was obtained using a
Hypersil C-18, 250 × 4.6 mm, 5 µm particle size column, provided with its own guard column (Thermo
Fisher Scientific, Rodano, Milan, Italy). The HPLC apparatus consisted of a SpectraSystem P4000 pump
system (ThermoFisher Scientific) and a highly-sensitive UV6000LP diode array detector (ThermoFisher
Scientific), equipped with 5 cm light path flow cell and set up between 200 and 300 nm wavelength.
Assignment and calculations of the compounds of interest in chromatographic runs of cell extracts
were performed at 260 nm wavelength by comparing retention times, absorption spectra, and area of
the peaks of chromatographic runs of mixtures containing known concentrations of true ultrapure
standard mixtures.
4.5. RNA Extraction and Real Time PCR Analysis
Total RNA was extracted from hippocampal slices using RNeasy®Mini Kit (QIAGEN, Manchester,
UK) according to the instructions of the manufacturer. RNA was dissolved in RNase-free water and
concentration and purity were determined with a ND-1000 UV–Vis Spectrophotometer (NanoDrop,
ThermoFisher Scientidic, Waltham, MO, USA). RNA extract was reversed transcribed to cDNA by
Superscript II Reverse Transcriptase Kit (Invitrogen). From each sample, 1 mg of total RNA, 500 ng of
oligo dT primers (Roche Molecular Biochemicals, Burgess Hill, UK), 4 µL of First Strand Buffer and
200 U of Superscript II Reverse Transcriptase in a total volume of 20 µL were incubated at 42 ◦C for
50 min and 70 ◦C for 15 min.
Real Time PCR with melting curve analysis was performed in Bio-Rad iQ5 Real-time PCR Detection
System (Bio-Rad, Hercules, CA, USA). In each reaction, 100 ng of cDNA sample was combined with a
reaction mixture containing 25 µL of 2× SYBR Green PCR Master Mix (Applied Biosystems, Warrington,
UK), each primer (at final concentration of 300 nM), and RNase-free water in a final volume of 50 µL.
The thermal profile began with incubation at 95 ◦C for 10 min, followed by 40 cycles of amplification
alternating between 94 ◦C for 15 s and 60 ◦C for 60 s. After amplification to confirm the specificity of
reactions, a melting curve was produced by conducting 81 cycles of 30 s of melting every 0.5 ◦C from
55 to 95 ◦C. Final data were analyzed by the iQ™5 Optical System Software (Bio-Rad). Primers for
PFKL (isoform L of 6-phosphofructo-1-kinase, NM_013190.4), ALDOC (aldolase C, NM_012497.1),
GAPDH (glyceraldehyde-3-phosphate dehydrogenase, NM_017008.4) were designed with the 0.2
version of the Primer3 Input software developed by the Whitehead Institute for Biomedical Research
(Cambridge, MA, USA) and using as template the sequences of Rattus norvegicus. For accurate
gene expression measurements with Real Time PCR, results were normalized to a fixed reference,
therefore the constitutively expressed housekeeping gene of Rattus norvegicus B2M (β-2-microglobulin,
NM_017314.1) was selected using the geNorm Housekeeping Gene Selection Kit (Primer Design
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Ltd., Southampton, UK) from a list containing 12 candidate reference genes. Changes in transcript
abundance of tested genes were calculated using the 2−∆∆CT method as described by Livak and
Schmittgen [64].
4.6. Statistics
The within group comparison at each time was performed by the one-way analysis of variance
(ANOVA). Differences across groups were estimated by the two-way ANOVA. Fisher’s protected
least square was used as the post hoc test. Only p-values of less than 0.05 were considered as
statistically significant.
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